SI
TVTX icon

Sofinnova Investments’s Travere Therapeutics TVTX Stock Holding History

Sofinnova Investments’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-32,616
Closed -$568K – 80
2024
Q4 		$568K Buy
+32,616
New +$577K 0.04% 58
2023
Q2 		– Sell
-1,263,721
Closed -$28.4M – 63
2023
Q1 		$28.4M Buy
1,263,721
+685,453
+119% +$14.6M 1.82% 14
2022
Q4 		$12.2M Buy
578,268
+183,590
+47% +$3.89M 0.72% 29
2022
Q3 		$9.72M Buy
394,678
+182,085
+86% +$4.7M 0.57% 34
2022
Q2 		$5.15M Sell
212,593
-445,656
-68% -$11.2M 0.43% 39
2022
Q1 		$17M Sell
658,249
-382,609
-37% -$10.2M 1.29% 21
2021
Q4 		$32.3M Buy
1,040,858
+603,578
+138% +$17M 1.89% 13
2021
Q3 		$10.6M Buy
+437,280
New +$8.03M 0.63% 35

Other funds holding TVTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Sofinnova Investments's TVTX Position: Q1 2025 in Review

Sofinnova Investments sold out of Travere Therapeutics (TVTX) in Q1 2025, closing a stake of 32,616 shares — an estimated $568K sold.

Sofinnova Investments first reported a position in TVTX in Q3 2021 and held it in 8 quarters. The position peaked at $32.3M in Q4 2021. 218 funds tracked by Wall St. Rank hold TVTX as of Q1 2025.

  • Sofinnova Investments reported no remaining Travere Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Sofinnova Investments sold 32,616 Travere Therapeutics shares in Q1 2025, an estimated $568K.
  • Sofinnova Investments first reported a position in Travere Therapeutics in Q3 2021 and held it in 8 quarters.
  • Sofinnova Investments's Travere Therapeutics position peaked at $32.3M in Q4 2021.
  • 218 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2025.

Based on Sofinnova Investments's 13F filing for Q1 2025, filed 15 May 2025.